AI and predictive analytics are transforming clinical data risk management. CRAs are essential to successful trial. Read more on how tech empowers, not replaces, the CRA. Read the ACT article: https://ow.ly/ESvn50XB6TW
- Home
- News & Events
- In the News
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
ICON announces results from survey on obesity-related clinical research
This news article, from Applied Clinical Trials, outlines findings from ICON’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
Patient centricity in insulin injection: Using technology to improve self-administration
David T. Novotny, General Manager & Global Head of ICON’s Medical Device and Diagnostic Research business unit, considers the current and future developments in injection technology.
-
Ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic
Jack Martin and Deirdre Albertson provide insights on ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic.
-
Mitigating the impact of COVID-19 on CV trials and participants
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19 by adopting patient-centric technologies to keep patients safe and studies on track. The article is published in PharmaFile Spring 2020 on page 40.
-
Adopting mHealth Technologies in CV Trials
A Pharmafile article authored by Marie McCarthy and Jack Martin on the use of mHealth technologies in cardiovascular trials. The article discusses how, with the right approach and expert guidance, mHealth can help to collect new types of data, make trials more patient centric (improving recruitment, retention and compliance) and improve operational efficiency.